麻豆传媒

Standard of care prevails in single-center trial

More patients taking sodium zirconium cyclosilicate achieved normokalemia vs placebo recipients

Benefit shown in trial of patients flagged for high risk of cardiotoxicity

Intranasal bumetanide demonstrated safety, bioequivalence with its oral and IV counterparts

One-time treatment with nexiguran ziclumeran tied to decline in serum TTR levels in phase I trial

SUMMIT trial able to show clinical benefit beyond quality-of-life improvement

Researchers try to address challenge of distinguishing HCM from other cardiomyopathies

Evoque device helped outcomes in severe tricuspid regurgitation, with some safety caveats

Anti-mineralocorticoid agent reduced albuminuria, but not eGFR-based kidney outcome

Effectiveness of this personalized approach now under investigation

Panelists acknowledge difficulty generating stronger data in ultra-rare disease

Agency appears unswayed by mitochondria-targeting drug for rare cardioskeletal disease

Benefit in symptoms, functional outcomes remains to be seen for HU6

Cardiac myosin inhibitor linked to improvements in biomarkers in small study